Laboratory Testing for Antiphospholipid Syndrome
Providing Confidence Through Outstanding Quality
These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.
Antiphospholipid syndrome (also known as APS, sticky blood syndrome, or Hughes Syndrome) is a thrombosis or blood-clotting disorder in which autoantibodies are produced to a variety of phospholipids and phospholipid-binding proteins.1 APS thrombosis is also related to women's health issues, such as pregnancy comorbidities.1
Why choose Thermo Fisher Scientific as your partner in antiphospholipid syndrome diagnostics?
The clinical performance of the EliA™ antiphospholipid portfolio provides reliable test results that aid in the diagnosis of antiphospholipid syndrome.2,3 The EliA antiphospholipid portfolio contains the essential first- and second-line tests for routine use and is fully automated on the Phadia™ Laboratory System.2,3
Fully automated portfolio to aid in the diagnosis of antiphospholipid syndrome (APS)
- EliA antiphospholipid covers the most essential four tests: EliA™ β2-Glycoprotein I IgG/IgM tests and EliA™ Cardiolipin IgG/IgM tests, which are required to be performed simultaneously to appropriately assist APS diagnosis.4
- The overall positive predictive values across EliA™ β2-Glycoprotein I IgG and IgM tests and EliA™ Cardiolipin IgG and IgM tests are balanced and have optimized clinical performance, helping your customers to put their patients first.5
Supporting you with the diagnosis of sero-negative antiphospholipid syndrome (APS)
- The broad, high-quality portfolio of EliA™ antiphospholipid tests includes EliA™ β2-Glycoprotein I IgA and EliA™ Cardiolipin IgA test, enabling you to detect antiphospholipid syndrome even when the IgG and IgM tests are negative.6
Consistent quality you can trust
- EliA™ antiphospholipid tests were designed following the international consensus guideline for manufacturers.6 EliA antiphospholipid tests provide you with consistent lot-to-lot quality as proven in internal and external quality assurance schemes—quality you can trust to provide the right result the first time.7
- Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018 May ;378(21):2010-2021.
- Villalta D, Alessio M G, Tampoia M, Re A Da, Stella S, Re M Da, et al. Accuracy of the First Fully Automated Method for Anti-Cardiolipin and anti-beta2 Glycoprotein I Antibody Detection for the Diagnosis of Antiphospholipid Syndrome. Ann N Y Acad Sci. 2009 Sep;1173:21-7.
- Pérez D, Martínez-Flores JA, Serrano M, Lora D, Paz-Artal E, Morales JM, et al. Evaluation of Three Fully Automated Immunoassay Systems for Detection of IgA Anti-Beta 2-glycoprotein I Antibodies. Int. Jnl. Lab. Hem. 2016 Oct;38(5):560-8.
- Gardiner C, Hills J, Machin SJ, Cohen H. Diagnosis of Antiphospholipid Syndrome in Routine Clinical Practice. Lupus . 2013 Jan;22(1):18-25.
- Montaruli B, Luna ED, Erroi L, Marchese C, Mengozzi G, Napoli P, et al. Analytical and Clinical Comparison of Different Immunoassay Systems for the Detection of Antiphospholipid Antibodies. 2016 Apr;38(2):172-82.
- Lakos G., Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International Consensus Guidelines on Anticardiolipin and anti-β2-glycoprotein I Testing: Report From the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012 Jan;64(1):1-10.
- Thermo Fisher Scientific, Quality Club data.
